Association of Immune-Related Adverse Events and the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Adjusting for Immortal Time Bias - PubMed
3 hours ago
- #Immortal Time Bias
- #Non-Small Cell Lung Cancer
- #Immune Checkpoint Inhibitors
- Study examines the association between immune-related adverse events (irAEs) and survival outcomes in NSCLC patients treated with ICIs, adjusting for immortal time bias (ITB).
- 129 advanced NSCLC patients receiving first-line ICIs were analyzed for irAE development and its impact on PFS and OS.
- Unadjusted analyses initially showed significant associations between irAEs and longer PFS and OS, but these associations disappeared after adjusting for ITB.
- Landmark analyses at 30, 42, and 75 days and time-dependent Cox models confirmed no significant survival benefits linked to irAE occurrence.
- Baseline performance status, not irAE development, was identified as a critical prognostic factor for survival in these patients.
- The study concludes that irAE development is not associated with improved survival in NSCLC patients treated with ICIs when ITB is properly accounted for.